

New research insights hold promise for kids with DMD

11 February 2019

Prednisone, the current standard of care used to treat kids with Duchenne muscular dystrophy (DMD), reduces chronic inflammation but has harsh side effects. Eplerenone, a heart failure drug, is used in older patients to treat cardiomyopathy, a leading cause of mortality for people with DMD. A new medicine under development appears to combine the beneficial effects of these drugs for the heart and muscle while also showing improved safety in experimental models. This drug, vamorolone, does so by simultaneously targeting two nuclear receptors important in regulating inflammation and cardiomyopathy, indicates a small study published online Feb. 11, 2019, in *Life Science Alliance*.

DMD is a progressive X-linked disease that occurs mostly in males. It is characterized by muscle weakness that worsens over time, and most kids with DMD will use wheelchairs by the time they're teenagers. DMD is caused by mutations in the *DMD* gene, which provides instructions for making dystrophin, a protein found mostly in skeletal, respiratory and heart muscles.

Cardiomyopathy, an umbrella term for diseases that weaken the heart, is a leading cause of death for young adults with DMD, causing up to 50 percent of deaths in patients who lack dystrophin. A collaborative research team co-led by Christopher R. Heier, Ph.D., and Christopher F. Spurney, M.D., of Children's National Health System, is investigating cardiomyopathy in DMD. They find genetic dystrophin loss provides "a second hit" for a specific pathway that worsens cardiomyopathy in [experimental models](#) of DMD.

"Some drugs can interact with both the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) since these two drug targets evolved from a common ancestor. However, we find these two drug targets can play distinctly different roles in heart and skeletal muscle. The GR regulates muscle inflammation, while the MR plays a key role

in heart health," says Heier, an assistant professor at Children's National and lead study author. "In our study, the experimental drug vamorolone safely targets both the GR to treat chronic inflammation and the MR to treat the heart."

After gauging the efficacy of various treatments in test tubes, the study team looked at whether any could mitigate negative impacts of the MR on heart health. Wild type and *mdx* experimental models were implanted with pumps that activated the MR. These models also received a daily oral MR antagonist (or inhibitor) drug, and either eplerenone, spironolactone or vamorolone. Of note:

- MR activation increased kidney size and caused elevated [blood pressure](#) (hypertension).
- Treatment with vamorolone maintained normal kidney size and prevented hypertension.
- MR activation increased *mdx* heart mass and fibrosis. Vamorolone mitigated these changes.
- MR activation decreased *mdx* heart function, while vamorolone prevented declines in function.
- Daily prednisone caused negative MR- and GR-mediated side effects, such as hyperinsulinemia, whereas vamorolone safely improved heart function without these side effects.

"These findings have the potential to help current and future patients," Heier says. "Clinicians already prescribe several of these drugs. Our new data support the use of MR antagonists such as eplerenone in protecting DMD hearts, particularly if patients take prednisone. The experimental [drug](#) vamorolone is currently in Phase IIb clinical trials and is particularly exciting for its unique potential to simultaneously treat [chronic inflammation](#) and [heart](#) pathology with improved safety."

More information: *Life Science Alliance*, [DOI: 10.26508/lsa.201800186](#)

Provided by Children's National Medical Center
APA citation: New research insights hold promise for kids with DMD (2019, February 11) retrieved 23 May 2019 from <https://medicalxpress.com/news/2019-02-insights-kids-dmd.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.